Evidence map›Paper›PMID 41692425›Full record

ArticleCancer medicine2026

Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.

Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi and 46 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

56 authors.

Hideko OhamaDepartment of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.ORCID https://orcid.org/0000-0002-1882-824X
Atsushi HiraokaDepartment of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.ORCID https://orcid.org/0000-0003-1989-0480
Toshifumi TadaDepartment of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.ORCID https://orcid.org/0000-0002-0976-6761
Masashi HirookaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Kazuya KariyamaDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan.ORCID https://orcid.org/0000-0003-3996-7502
Joji TaniDepartment of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.
Masanori AtsukawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3374-7111
Koichi TakaguchiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Ei ItobayashiDepartment of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Shinya FukunishiDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Kunihiko TsujiCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Toru IshikawaDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Kazuto TajiriDepartment of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Hironori TanakaDepartment of Gastroenterology, Takarazuka City Hospital, Takarazuka, Hyogo, Japan.
Hidenori ToyodaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.ORCID https://orcid.org/0000-0002-1652-6168
Chikara OgawaDepartment of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Takashi NishimuraDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.ORCID https://orcid.org/0000-0002-5517-8303
Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.ORCID https://orcid.org/0000-0003-3656-285X
Satoru KakizakiDepartment of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.ORCID https://orcid.org/0000-0003-0224-7093
Kazuhito KawataHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Atsushi NaganumaDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan.ORCID https://orcid.org/0000-0003-0663-0102
Hisashi KosakaDepartment of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan.
Tomomitsu MatonoDepartment of Hepatology, Harima Himeji General Medical Center, Himeji, Japan.
Hidekatsu KurodaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.
Yutaka YataDepartment of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0002-4592-3509
Hiroki NishikawaDepartment of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Michitaka ImaiDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tomoko AokiDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Hironori OchiCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Hideyuki TamaiDepartment of Hepatology, Wakayama Rosai Hospital, Wakayama, Japan.ORCID https://orcid.org/0000-0003-4511-4573
Shohei KomatsuDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Fujimasa TadaDepartment of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.ORCID https://orcid.org/0009-0007-3964-5876
Shinichiro NakamuraDepartment of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Yoshiko NakamuraDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Teruki MiyakeDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Osamu YoshidaDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Kazuhiro NousoDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan.ORCID https://orcid.org/0000-0002-2018-0008
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.
Norio ItokawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Tomomi OkuboDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Taeang AraiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Akemi TsutsuiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Takuya NaganoDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Kazunari TanakaCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Takanori MatsuuraDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0009-0008-7361-881X
Yuichi KoshiyamaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Yuki KanayamaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Hidenao NoritakeHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hirayuki EnomotoDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Kosuke MatsuiDepartment of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan.
Masaki KaiboriDepartment of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan.
Takumi FukumotoDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Yoichi HiasaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0000-0003-4117-339X
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Takashi KumadaGifu Kyoritsu University, Ogaki, Japan.
RELPEC Group and HCC 48 Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFindings regarding long-term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was performed to evaluate results regarding 3 year survival of such patients treated in real-world clinical settings.

methodsThis multicenter retrospective study included 555 patients with Child-Pugh A and BCLC stage B or C, for whom Atez/Bev treatment was initiated in the period from 2020 to 2021. Best treatment response, progression-free survival (PFS), overall survival (OS), post-progression survival (PPS), and immune-related adverse events (irAEs) were analyzed.

resultsMedian age was 73 years and 80.2% were male. Atez/Bev was given as first-line therapy in 55.3%. Objective response rate (ORR) was 41.3% and disease control rate (DCR) was 79.4%. Median PFS was 6.2 months, while median OS was 21.6 months with a 3 year survival rate of 29.7%. Patients treated with Atez/Bev as first-line therapy showed a higher 3 year survival rate of 35.9%. Post-progression treatment was administered to 54.1% of the patients and median PPS in those was 10.9 months. Conversion therapy was performed in 5.9%. IrAEs occurred in 13.3% (grade 5: 0.7%).

conclusionsuHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long-term survival with a 3 year survival rate of approximately 30%, including 35.9% for first-line users.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabatezolizumab plus bevacizumabdurvalumab plus tremelimumabhepatocellular carcinomaIMbrave150 trialprognosis

Identifiers

PMID41692425
PMCPMC12906954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.